Anti‐vascular endothelial growth factor therapy vs conventional laser/cryotherapy: Mortality at 30 months of age
Anti‐vascular endothelial growth factor therapy showed no clear difference in mortality at 30 months of age compared with conventional laser/cryotherapy (low certainty).
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Anti‐vascular endothelial growth factor therapy vs conventional laser/cryotherapy Mortality at 30 months of age · preterm infants with type 1 ROP Anti‐vascular endothelial growth factor therapy showed no clear difference in mortality at 30 months of age compared with conventional laser/cryotherapy (low certainty). Anti‐vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity (2018) · Cochrane Headline outcomes only | RR 0.86 [0.3, 2.45] | 1 study · 150 participants | Low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Anti‐vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity 2018 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.